1. Report Overview
1.1 Introduction to Non-alcoholic Fatty Liver Disease & NASH Market
1.2 Non-alcoholic Fatty Liver Disease & NASH Market Definition
1.3 Global Market Overview
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Executive Summary
2.1 Key Highlights
3 Non-alcoholic Fatty Liver Disease & NASH Industry Overview
3.1 Overview
3.1.1 Risk Factors for NAFLD & NASH
3.1.2 Diagnosis and Staging of NAFLD/NASH
3.1.3 Imaging Assessment of Steatosis
3.1.4 Liver biopsy for NAFLD
3.1.5 A Pragmatic Approach To Diagnosis And Staging Of NAFLD In Clinical Practice
3.2 COVID-19 Impact of Liver Diseases
4 Market Drivers, Restraints and Opportunities
4.1 Overview
4.2 Increase in number of patients affected by NASH
4.3 Rising Healthcare Expenditure
4.4 Rising Studies And Drugs Developments
4.5 Absence Of Low-Cost And Definitive Diagnostic Methods
4.6 Challenge Due To Regulatory Bodies And Drug Approval
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants – Low
4.7.2 Bargaining Power of Suppliers – Low
4.7.3 Bargaining Power of Buyers – Moderate
4.7.4 Threat of Substitutes – Moderate to Low
4.7.5 Competitive Rivalry – High
5 Global Non-alcoholic Fatty Liver Disease & NASH Market Analysis
5.1 Global Market Overview
5.2 Global Market Estimation & Forecast
5.2.1 Pre-COVID Market Analysis
5.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
5.3 Regional Market Analysis
5.3.1 Pre-COVID Market Analysis
5.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.4 Global Market Breakdown by Disease Cause
5.4.1 Pre-COVID Market Analysis
5.4.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.4.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.5 Global Market Breakdown by Drug Type
5.5.1 Pre-COVID Market Analysis
5.5.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.5.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.6 Global Market Breakdown by Sales Channel
5.6.1 Pre-COVID Market Analysis
5.6.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.6.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6 North America Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.1 North America Market Overview
6.2 North America Market Estimation & Forecast
6.2.1 Pre-COVID Market Analysis
6.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
6.3 North America Market Breakdown by Country
6.3.1 Pre-COVID Market Analysis
6.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.4 North America Market Breakdown by Disease Cause
6.4.1 Pre-COVID Market Analysis
6.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.5 North America Market Breakdown by Drug Type
6.5.1 Pre-COVID Market Analysis
6.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.6 North America Market Breakdown by Sales Channel
6.6.1 Pre-COVID Market Analysis
6.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.7 US Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.7.1 US Market Outlook
6.7.2 Pre-COVID Market Analysis
6.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.8 Canada Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.8.1 Canada Market Outlook
6.8.2 Pre-COVID Market Analysis
6.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7 Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.1 Europe Market Overview
7.2 Europe Market Estimation & Forecast
7.2.1 Pre-COVID Market Analysis
7.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
7.3 Europe Market Breakdown by Country
7.3.1 Pre-COVID Market Analysis
7.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.4 Europe Market Breakdown by Disease Cause
7.4.1 Pre-COVID Market Analysis
7.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.5 Europe Market Breakdown by Drug Type
7.5.1 Pre-COVID Market Analysis
7.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.6 Europe Market Breakdown by Sales Channel
7.6.1 Pre-COVID Market Analysis
7.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.7 Germany Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.7.1 Germany Market Outlook
7.7.2 Pre-COVID Market Analysis
7.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.8 UK Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.8.1 UK Market Outlook
7.8.2 Pre-COVID Market Analysis
7.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.9 France Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.9.1 France Market Outlook
7.9.2 Pre-COVID Market Analysis
7.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.10 Italy Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.10.1 Italy Market Outlook
7.10.2 Pre-COVID Market Analysis
7.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.11 Spain Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.11.1 Spain Market Outlook
7.11.2 Pre-COVID Market Analysis
7.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.12 Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.12.1 Rest of Europe Market Outlook
7.12.2 Pre-COVID Market Analysis
7.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8 Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.1 Asia-Pacific Market Overview
8.2 Asia-Pacific Market Estimation & Forecast
8.2.1 Pre-COVID Market Analysis
8.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
8.3 Asia-Pacific Market Breakdown by Country
8.3.1 Pre-COVID Market Analysis
8.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
8.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.4 Asia-Pacific Market Breakdown by Disease Cause
8.4.1 Pre-COVID Market Analysis
8.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.5 Asia-Pacific Market Breakdown by Drug Type
8.5.1 Pre-COVID Market Analysis
8.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.6 Asia-Pacific Market Breakdown by Sales Channel
8.6.1 Pre-COVID Market Analysis
8.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.7 China Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.7.1 China Market Outlook
8.7.2 Pre-COVID Market Analysis
8.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.8 India Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.8.1 India Market Outlook
8.8.2 Pre-COVID Market Analysis
8.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.9 Japan Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.9.1 Japan Market Outlook
8.9.2 Pre-COVID Market Analysis
8.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.10 South Korea Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.10.1 South Korea Market Outlook
8.10.2 Pre-COVID Market Analysis
8.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.11 Australia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.11.1 Australia Market Outlook
8.11.2 Pre-COVID Market Analysis
8.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.12 Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.12.1 Rest of Asia-Pacific Market Outlook
8.12.2 Pre-COVID Market Analysis
8.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9 LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.1 LAMEA Market Overview
9.2 LAMEA Market Estimation & Forecast
9.2.1 Pre-COVID Market Analysis
9.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
9.3 LAMEA Market Breakdown by Country
9.3.1 Pre-COVID Market Analysis
9.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.4 LAMEA Market Breakdown by Disease Cause
9.4.1 Pre-COVID Market Analysis
9.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.5 LAMEA Market Breakdown by Drug Type
9.5.1 Pre-COVID Market Analysis
9.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.6 LAMEA Market Breakdown by Sales Channel
9.6.1 Pre-COVID Market Analysis
9.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.7 Brazil Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.7.1 Brazil Market Outlook
9.7.2 Pre-COVID Market Analysis
9.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.8 Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.8.1 Saudi Arabia Market Outlook
9.8.2 Pre-COVID Market Analysis
9.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.9 South Africa Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.9.1 South Africa Market Outlook
9.9.2 Pre-COVID Market Analysis
9.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.10 Mexico Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.10.1 Mexico Market Outlook
9.10.2 Pre-COVID Market Analysis
9.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.11 UAE Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.11.1 UAE Market Outlook
9.11.2 Pre-COVID Market Analysis
9.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.12 Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.12.1 Rest of LAMEA Market Outlook
9.12.2 Pre-COVID Market Analysis
9.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
10 Key Company Profiles
10.1 Pfizer Inc Company
10.1.1 Company Snapshot
10.1.2 Company Overview
10.1.3 Company Financial Profile
10.1.4 Company Product Benchmarking
10.1.5 Company Recent Developments
10.2 F. Hoffmann-La Roche Ltd Company
10.2.1 Company Snapshot
10.2.2 Company Overview
10.2.3 Company Financial Profile
10.2.4 Company Product Benchmarking
10.2.5 Company Recent Developments
10.3 Takeda Pharmaceuticals Company
10.3.1 Company Snapshot
10.3.2 Company Overview
10.3.3 Company Financial Profile
10.3.4 Company Product Benchmarking
10.3.5 Company Recent Developments
10.4 Intercept Pharmaceuticals, Inc. Company
10.4.1 Company Snapshot
10.4.2 Company Overview
10.4.3 Company Financial Profile
10.4.4 Company Product Benchmarking
10.5 AstraZeneca Pharmaceuticals Company
10.5.1 Company Snapshot
10.5.2 Company Overview
10.5.3 Company Financial Profile
10.5.4 Company Product Benchmarking
10.5.5 Company Recent Developments
10.6 Novartis Pharmaceutical Company
10.6.1 Company Snapshot
10.6.2 Company Overview
10.6.3 Company Financial Profile
10.6.4 Company Product Benchmarking
10.6.5 Company Recent Developments
10.7 Merck & Co. Company
10.7.1 Company Snapshot
10.7.2 Company Overview
10.7.3 Company Financial Profile
10.7.4 Company Product Benchmarking
10.7.5 Company Recent Developments
10.8 AbbVie Inc Company
10.8.1 Company Snapshot
10.8.2 Company Overview
10.8.3 Company Financial Profile
10.8.4 Company Product Benchmarking
10.8.5 Company Recent Developments
10.9 Gilead Science Inc Company
10.9.1 Company Snapshot
10.9.2 Company Overview
10.9.3 Company Financial Profile
10.9.4 Company Product Benchmarking
10.9.5 Company Recent Developments
10.10 Genfit Biotechnology Company
10.10.1 Company Snapshot
10.10.2 Company Overview
10.10.3 Company Financial Profile
10.10.4 Company Product Benchmarking
10.10.5 Company Recent Developments
10.11 Cardax Inc Pharmaceutical Company
10.11.1 Company Snapshot
10.11.2 Company Overview
10.11.3 Company Financial Profile
10.11.4 Company Product Benchmarking
10.12 Daewoong Co Ltd Company
10.12.1 Company Snapshot
10.12.2 Company Overview
10.12.3 Company Financial Profile
10.12.4 Company Product Benchmarking
10.12.5 Company Recent Developments
10.13 Madrigal Pharmaceuticals, Inc Company
10.13.1 Company Snapshot
10.13.2 Company Overview
10.13.3 Company Product Benchmarking
10.14 Mirum Pharmaceuticals Inc Company
10.14.1 Company Snapshot
10.14.2 Company Overview
10.14.3 Company Recent Developments
10.15 GW Pharmaceuticals Company
10.15.1 Company Snapshot
10.15.2 Company Overview
10.15.3 Company Financial Profile
10.15.4 Company Product Benchmarking
10.15.5 Company Recent Developments
11 Conclusion & Recommendations
11.1.1 Market Share Analysis, 2021,2026 & 2031 (%)
12 Glossary
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer